一、董事会会议召开情况 杭州安杰思医学科技股份有限公司（以下简称"公司"）第三届董事会第八 次会议于 2026 年 1 月 9 日以现场结合通讯的方式在公司九楼会议室召开。本次 会议通知及相关材料已于 2025 年 12 月 31 日以专人送达方式通知公司全体董事， 与会的各位董事已知悉与所议事项相关的必要信息。会议由董事长张承主持，会 议应到董事 5 人，实际出席董事 5 人，公司高级管理人员列席了本次会议。本次 会议的召集和召开程序符合《公司法》和《公司章程》的有关规定。 证券代码：688581 证券简称：安杰思 公告编号：2026-004 杭州安杰思医学科技股份有限公司 第三届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 会议审议以下议案并形成决议： 二、董事会会议审议情况 （一）审议了《关于向控股子公司增资暨关联交易的议案》 董事会认为：公司为满足控股子公司杭安医学业务发展的需要，进一步增强 杭安医学以 AI 临床诊断为核心的项目研发、市场拓展、产品量产等方面的综合 实力，拟以自有资金 ...

安杰思公告称，为满足控股子公司杭安医学日常经营及项目投资建设需要，公司拟为其申请综合授信额 度提供不超3.6亿元担保，担保可循环滚动使用。杭安医学成立于2023年8月，安杰思持股90.9091%。截 至2025年11月30日，杭安医学资产总额4562.06万元，负债总额5504.64万元。2026年1月9日公司董事会 已审议通过该议案，尚需股东会审议。截至公告披露日，公司无对外担保及逾期担保。 ...

（文章来源：证券日报） 证券日报网讯 1月5日，安杰思在互动平台回答投资者提问时表示，截至2025年12月31日，公司股东人 数为6367户。 ...

12月31日，安杰思跌1.08%，截至发稿，报58.59元/股，成交2297.36万元，换手率0.94%，总市值47.53 亿元。 资料显示，杭州安杰思医学科技股份有限公司位于浙江省杭州市临平区兴中路389号，成立日期2010年 12月6日，上市日期2023年5月19日，公司主营业务涉及从事内镜微创诊疗器械的研发、生产与销售。主 营业务收入构成为：GI类62.74%，EMR/ESD类23.26%，ERCP类11.04%，仪器类2.21%，其他0.74%。 从基金十大重仓股角度 数据显示，华泰保兴基金旗下1只基金重仓安杰思。华泰保兴健康消费A（006882）三季度持有股数 3640股，占基金净值比例为6.03%，位居第六大重仓股。根据测算，今日浮亏损失约2329.6元。 华泰保兴健康消费A（006882）成立日期2019年5月27日，最新规模74.14万。今年以来亏损14.34%，同 类排名8076/8085；近一年亏损15.05%，同类排名8073/8085；成立以来亏损10.2%。 华泰保兴健康消费A（006882）基金经理为赵旭照。 截至发稿，赵旭照累计任职时间7年353天，现任基金资产总规模6.53亿元 ...

Core Viewpoint - The company Anjies (688581.SH) announced that its subsidiary Hang'an Medical Technology (Hangzhou) Co., Ltd. has received medical device registration certificates from the Zhejiang Provincial Drug Administration for several endoscopic products, enhancing its product line in the endoscopy field [1] Group 1 - The registered products include an electronic endoscope image processor, an upper gastrointestinal electronic endoscope, and a lower gastrointestinal electronic endoscope [1] - The acquisition of these medical device registration certificates enriches the company's product offerings in the endoscopy diagnosis and treatment sector, addressing diverse clinical needs [1] - This development is expected to improve the company's overall market competitiveness and positively impact its sustainable growth [1]

Core Viewpoint - Anjias (688581.SH) has received medical device registration certificates for its electronic endoscope imaging processor and both upper and lower gastrointestinal electronic endoscopes, indicating a significant advancement in its product offerings in the endoscopy field [1][2]. Group 1: Company Developments - The registration certificates include the endoscope main unit (including imaging processor and light source), upper gastrointestinal electronic endoscope, lower gastrointestinal electronic endoscope, and peripheral equipment, aimed at early cancer diagnosis and treatment [1]. - The acquisition of these medical device registration certificates enhances the company's product line in the endoscopy sector, catering to diverse clinical needs and improving overall market competitiveness [2]. Group 2: Industry Insights - The endoscope and endoscopic treatment consumables market in China is experiencing rapid growth, driven by strong government support and increased R&D investment from domestic manufacturers [1]. - Domestic core products are gradually matching the performance parameters of foreign brands, with some key technologies achieving industry leadership, significantly enhancing market competitiveness and accelerating the process of domestic substitution [1].

证券日报网讯12月24日，安杰思在互动平台回答投资者提问时表示，截至2025年12月20日，公司的股东 人数为6529户。 ...

Core Viewpoint - The company Anjisi (688581.SH) has received medical device registration certificates for its endoscopic products, indicating a significant advancement in its product offerings and competitiveness in the domestic market [1][2]. Group 1: Product Registration - Anjisi's subsidiary Hang'an Medical has obtained medical device registration certificates for three products: electronic endoscope image processor, upper gastrointestinal electronic endoscope, and lower gastrointestinal electronic endoscope [1]. - The registration numbers for these products are: 20252062013 for the image processor, 20252062011 for the upper endoscope, and 20252062012 for the lower endoscope [1]. Group 2: Market Growth and Competitive Position - The endoscope and related diagnostic consumables market in China is experiencing rapid growth, driven by strong government support and increased R&D investment from domestic manufacturers [1]. - Domestic core products are gradually matching the performance parameters of foreign brands, with some key technologies achieving industry leadership, significantly enhancing market competitiveness and accelerating the process of domestic substitution [1]. Group 3: Impact on Company Development - The acquisition of these medical device registration certificates enriches the company's product line in the endoscopy field, meeting diverse clinical needs and enhancing overall market competitiveness [2]. - This development is expected to have a positive impact on the company's sustainable growth [2].

Core Viewpoint - Anjie's subsidiary, Hangzhou Anji Medical Technology Co., Ltd., has received a medical device registration certificate from the Zhejiang Provincial Drug Administration, enhancing its product line in the endoscopy field and improving market competitiveness [1] Group 1: Product Registration - The medical device registration certificate is valid from December 23, 2025, to December 22, 2030 [1] - The registered products include electronic endoscope image processors, upper gastrointestinal electronic endoscopes, and lower gastrointestinal electronic endoscopes [1] Group 2: Product Functionality - These products are designed to process signals from electronic endoscopes, provide illumination, and work in conjunction with image processors to display images for observation, diagnosis, and treatment of the upper and lower gastrointestinal tracts [1] Group 3: Market Impact - The acquisition of the registration certificate enriches the company's product line in the endoscopy sector, which is expected to enhance its overall competitiveness in the market [1]

证券代码：688581 证券简称：安杰思 公告编号：2025-068 | 序 | 产品名称 | 证书编号 | 注册证有效期 | 注册分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 号 | | | | | | | | | | | | 察、诊断和治疗用。 | 二、对公司的影响 目前，我国窥镜设备及内镜下诊疗耗材市场保持高速增长态势，在国家政策 大力扶持与国产厂商持续加大研发投入的双重驱动下，国内自主研发的核心产品 在整体性能参数上已逐步对标外资品牌，部分关键技术实现行业领先，市场竞争 力显著增强，国产替代进程明显提速。 上述医疗器械注册证的取得主要包括内镜主机（含图像处理器和光源）、内 镜镜体（含上消化道电子内窥镜和下消化道电子内窥镜）及内镜周边设备，用于 早癌诊断和治疗。其中，借助高性能硬平台电子光学系统，可在医生经验的基础 上提高诊断的敏感性和特异性，以保障诊断的正确率，在图像、操控性、智能化 等方面的创新与升级，为内镜诊疗打造了高画质与高效率的平台。 杭州安杰思医学科技股份有限公司 关于获得医疗器械注册证的自愿性披露公告 本公司董事会及全体董事保证本公 ...